Plamotamab

帕拉莫妥单抗

Report date: 2026/05/13 20:02:10

Base Information

Drug NamePlamotamab
Drug Alias NamePlamotamab - XencorXmAb-13676
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-CD3CD20-directed cytolytic effectsAnti-CD20
TargetsT cell surface glycoprotein CD3B-lymphocyte antigen CD20
Therapy Area/IndicationsScleroderma, SystemicMyositisSjogren's Syndrome +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNew ZealandAustralia +[8] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesXencor Inc
China Registration ClassN/A

Develop Information

Active CompaniesXencor IncNovartis Pharma AgJanssen Biotech Inc
Inactive CompaniesN/A
Active IndicationsScleroderma, SystemicMyositisSjogren's Syndrome +[6] 
Inactive IndicationsLymphoma, Large B-Cell, Diffuse

Other Information

ATC CodeN/A
Related LinksN/A